Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea
Authors:
- Suk Young LeeSLSuk Young Lee
- Ju Won KimJKJu Won Kim
- Yoon Ji ChoiYCYoon Ji Choi
- In Hae ParkIPIn Hae Park
- Keun Seok LeeKLKeun Seok Lee
- Jae Hong SeoJSJae Hong Seo
- Sang Won ShinSSSang Won Shin
- Yeul Hong KimYKYeul Hong Kim
- Jun Suk KimJKJun Suk Kim
- Kyong Hwa ParkKPKyong Hwa Park
- 14 September 2016
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 91 (5) , 274-282
Abstract
Objective: This retrospective study was undertaken to assess the incidence of and risk factors for febrile neutropenia (FN) during adjuvant chemotherapy for early-stage breast cancer (ESBC). Methods: A multicenter survey of three tertiary hospitals was conducted, with data extracted from the records of ESBC patients treated with adjuvant chemotherapy containing AC (doxorubicin, 60 mg/m2 and cyclophosphamide, 600 mg/m2 every 21 days). Assessments included clinical characteristics, chemotherapy dose modifications, and incidence of FN. Results: A total of 610 patients were included for analysis. The incidence of grade 4 neutropenia and FN was 44.6 and 8.5%, respectively. Reduced relative dose intensity (RDI) less than 85% occurred in 11.0% of patients, and there were treatment delays in 12.6% of patients. Multivariate analysis identified several independent predictors for FN, including the presence of grade 4 neutropenia and pretreatment calculated estimated glomerular filtration rate less than 60 ml/min. Conclusion: Patients with ESBC are at substantial risk for FN and reduced RDI when treated with adjuvant AC chemotherapy. Predictive models based on risk factors identified in this study should enable the selective application of supportive measures in an effort to deliver the full dose of chemotherapy.Keywords
This publication has 26 references indexed in Scilit:
- Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010Cancer Research and Treatment, 2013
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal of Cancer, 2011
- Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapyCancer, 2010
- Dose Intensity in Early-Stage Breast Cancer: A Community Practice ExperienceJournal of Oncology Practice, 2009
- Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of ChemotherapyClinical Cancer Research, 2009
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Effect of Creatinine Clearance on Patterns of Toxicity in Older Patients Receiving Adjuvant Chemotherapy for Breast CancerDrugs & Aging, 2005
- Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community PracticesJournal of Clinical Oncology, 2003
- Chemotherapy dose reduction and delay in clinical practiceEuropean Journal of Cancer, 2000
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995